Several PHD inhibitors are currently in clinical trials for the treatment of renal anemia and ischemic disease.175,176 PHD inhibitors such as Vadadustat, Daprodustat, Molidustat and Roxadustat are all in phase 3 clinical trials for patients with renal anemia secondary to chronic kidney disease. The gene discussed is PDC; the disease is chronic kidney disease.